Effects of chronic endothelin ET(A) receptor blockade on blood pressure and vascular formation of cyclic guanosine-3',5'-monophosphate in spontaneously hypertensive rats.

Michael Kirchengast, Klaus Witte, Kerstin Stolpe, Lothar Schilling, Pavel I Nedvetsky, Harald H H W Schmidt, Björn Lemmer

Institute of Pharmacology and Toxicology, Ruprecht Karls University Heidelberg, Mannheim, Germany.

Journal Article: Arzneimittel-Forschung (impact factor: 0.69). 02/2005; 55(9):498-504.

Abstract

Endothelin (ET) mediates vasoconstriction in intact arterial blood vessels with functional endothelium via stimulation of ET(A) receptors, while ET(B) receptor stimulation leads to vasodilation via nitric oxide (NO) release and formation of cyclic guanosine-3',5'-monophosphate (cGMP). In spontaneously hypertensive rats (SHR) the cGMP-forming NO-receptor guanylyl cyclase (sGC) is downregulated. It is unclear whether ET contributes to the hypertensive phenotype of SHR, and whether this involves the disturbed cGMP signaling. The selective ETA receptor antagonist darusentan (CAS 171714-84-4), given orally via drinking water (10 mg kg(-1) d(-1)) for 12 weeks, significantly lowered systolic blood pressure of SHR as determined by radiotelemetry. Neither impaired endothelium-dependent relaxation to acetylcholine was restored nor sGC expression and activity affected when compared to control SHR. While these findings show a role for ETA receptors in blood pressure regulation in genetically elevated blood pressure, downregulation of sGC expression and cGMP-mediated vasorelaxant response in SHR were shown to be independent of ETA receptors. The findings suggest distinct mechanisms of gene expression affecting ET and cGMP mediated vasomotor functions.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

acetylcholine
 
blood pressure
 
blood pressure regulation
 
cGMP
 
cGMP-forming NO-receptor guanylyl cyclase
 
cGMP-mediated vasorelaxant response
 
disturbed cGMP signaling
 
downregulation
 
endothelium-dependent relaxation
 
ET contributes
 
ETA receptors
 
gene expression
 
hypertensive phenotype
 
intact arterial blood vessels
 
nitric oxide
 
selective ETA receptor antagonist darusentan
 
spontaneously hypertensive rats
 
systolic blood pressure
 
vasodilation
 
vasomotor functions